跳至主要内容
临床试验/NL-OMON53150
NL-OMON53150已完成3 期

Multicenter Randomized CLinical trial of endovascular treatment for acute ischemic stroke in the Netherlands. The effect of periprocedural MEDication: heparin, antiplatelet agents, both or neither. - MR CLEAN-MED

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 1,500 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
1,500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • a clinical diagnosis of acute ischemic stroke; caused by proximal intracranial
  • anterior circulation occlusion (distal intracranial carotid artery or middle
  • (M1/proximal M2) or anterior (A1/A2) cerebral artery confirmed by neuro-imaging
  • (CTA or MRA); CT or MRI ruling out intracranial hemorrhage; treatment possible
  • (groin puncture) within 6 hours from symptom onset or last seen well; a score
  • of at least 2 on the NIH Stroke Scale; age of 18 years or older; written
  • informed consent (deferred).

排除标准

  • - Pre-stroke disability which interferes with the assessment of functional
  • outcome at 90 days, i.e. mRS >2;
  • - Treatment with IV alteplase, despite the following contra-indications for IV
  • alteplase: cerebral infarction in the previous 6 weeks with residual
  • neurological deficit or signs of recent infarction on neuroimaging, previous
  • intracerebral hemorrhage in the previous 3 months, INR exceeding 1.7, prior use
  • of direct oral anticoagulant (DOAC)
  • - IV alteplase infusion >4.5 hours after symptom onset;
  • - Contra-indications for ASA/unfractionated heparin, for instance: allergy,
  • recent hemorrhage, heparin induced thrombocytopenia;
  • - INR exceeding 3.0
  • - Known hemorrhagic diathesis or known thrombopenia (<90^9/L)
  • - Therapeutic heparin use

研究者

相似试验

Multicenter Randomized CLinical trial of... | 临床试验